News
Novo Nordisk's (NVO) weight loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries who are both obese and have cardiovascular disease, could cost the system up to $145B ...
Recent health news includes trade restrictions on Brazilian chicken due to bird flu, potential U.S. tariffs on ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
Novo Nordisk anticipates that the next round of medications targeted ... the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D for the first ...
How the change could impact Novo Nordisk. The amount Medicare spent on Ozempic, Wegovy, and Rybelsus between November 2023 and October 2024 represents roughly 36% of Wall Street's consensus ...
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.
Medicare is negotiating the prices of 15 drugs, including Novo Nordisk's Ozempic.The government has until Nov. 30 to announce the agreed-upon Medicare prices. The lower prices would go into effect ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results